Nordic Bioproducts Group shortlisted as CPHI Pharma Awards 2024 Finalist for sustainability
This recognition highlights the breakthrough of the company’s Microcrystalline Cellulose (MCC) production at their new production facility, powered by the patented AaltoCell™ technology.ESPOO, Finland (October 9th, 2024) Nordic Bioproducts Group (NBG) has announced that it was selected as one of the finalists at the CPHI Pharma Awards 2024 in the sustainability category. The recognition came from the company’s pioneering work at their new production facility in Lappeenranta, Finland, where NBG’s Microcrystalline Cellulose (MCC) is being produced, amongst